Table 1. Main characteristics of 43 patients with tegumentary leishmaniasis treated with liposomal amphotericin B.

Characteristics of patients		n = 43
Demographics
	Median age, years [range]	51 [1–86]
	Male	29 (67)
	Cardiovascular comorbidities and/or diabetes	7 (16)
	Immunocompromised subject	5 (12)
	Child	6 (14)
Clinical form
	Localized cutaneous	32 (74)
	Mucocutaneous	8 (19)
	Disseminated cutaneous	2 (5)
	Localized cutaneous with visceral involvement	1 (2)
Area where infection was acquired
	Old World	28 (65)
	New World	15 (35)
Leishmania Species (n = 35; 8 species unidentified)
	L. braziliensis	11 (31)
	L. braziliensis complex	2 (6)
	L. guyanensis	1 (3)
	L. amazonensis	1 (3)
	L. infantum	9 (26)
	L. major	6 (17)
	L. tropica	3 (8)
	L. donovani	2 (6)
Clinical findings
	Number of lesions, median [range]	2 [1–30]
	Larger lesion size (millimeter), median [range]	30 [4–200]
Treatment
	Frontline therapy with L-AmB	30 (70)
	Liposomal AmB cumulative dose (mg/kg), median [range]	20 [6–56]
	Number of infusions, median [range]a	6 [2–14]
Outcome
	Follow-up (days), median [range]	79 [28–803]
	Complete healing without relapse	19 (44)
	Improvement	2 (5)
	Failure	17 (39)
	Relapse	5 (12)
Adverse events
	Patients with at least one adverse event	23 (53)
	Treatment modification due to adverse events	7 (16)

L-AmB, liposomal amphotericin B. Data are n (%) unless otherwise indicated.

^a this information was available for 24 patients